DG-041 is a potent and selective EP3 receptor antagonist, exhibiting IC50 values of 4.6 nM and 8.1 nM in binding and functional assays, respectively. It effectively inhibits PGE2-mediated platelet aggregation in vitro and demonstrates blood-brain barrier permeability, supporting its utility in researching thrombosis and neuroinflammatory models.